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Introduction
Stroke is a major medical and economic burden being the fourth 
leading cause of mortality in the United Kingdom and leaving 
almost two-thirds of stroke survivors with a disability (Stroke 
Association, 2017). Despite extensive research for neuroprotec-
tive strategies, therapeutic options for acute ischaemic stroke 
remain limited and consist of recanalisation of the occluded ves-
sel thereby improving revascularisation to the ischaemic terri-
tory. This can be achieved either pharmacologically, through the 
use of tissue plasminogen activator (rt-PA), or via surgical 
removal of the blood clot (e.g. endovascular thrombectomy) 
(Asadi et al., 2016). Recanalisation treatments are limited by a 
very narrow therapeutic time window (<4.5 hr for rt-PA or <6 hr 
for endovascular thrombectomy), thereby reducing treatment 
options for many patients. Therapies aimed at improving the sur-
vival of brain tissue located within the at-risk, but potentially sal-
vageable penumbra are still desperately needed.
Ischaemia results in a rapid and profound depletion in adeno-
sine triphosphate (ATP), the energy currency of the cell (Phillis 
et al., 1996a; Xing et al., 2012). The inability to fuel the activity 
of the Na+/K+ ATPase results in neuronal depolarisation leading 
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Background: Cerebral ischaemia results in a rapid and profound depletion of adenosine triphosphate (ATP), the energy currency of the cell. This 
depletion leads to disruption of cellular homeostasis and cell death. Early replenishment of ATP levels might therefore have a neuroprotective effect in 
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with the xanthine oxidase inhibitor allopurinol (RibAdeAll; to further increase the availability of ATP precursors), could improve outcome in an in vivo 
rodent model of transient cerebral ischaemia.
Methods: After 60 min occlusion of the middle cerebral artery, and upon reperfusion, rats were administered saline, RibAde, or RibAdeAll for 6 h. 
Baseline lesion volume was determined by diffusion-weighted MRI prior to reperfusion and final infarct volume determined by T2-weighted MRI at Day 
7. Neurological function was assessed at Days 1, 3 and 7.
Results: Ischaemic lesion volume decreased between Days 1 and 7: a 50% reduction was observed for the RibAdeAll group, 38% for the RibAde group 
and 18% in the animals that received saline. Reductions in lesion size in treatment groups were accompanied by a trend for faster functional recovery.
Conclusion: These data support the potential use of ribose, adenine and allopurinol in the treatment of cerebral ischaemic injury, especially since all 
compounds have been used in man.
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to pathological changes in ionic homeostasis and acute cell death 
in the ischaemic core (Doyle et al., 2008; Pulsinelli, 1992). 
Beyond the core, the adjacent penumbra is at risk via hypoperfu-
sion and waves of ischaemic depolarisation – also known as peri-
infarct depolarisations – that impose high energetic demands 
upon poorly perfused and energetically compromised brain tis-
sue. This results in recruitment of the otherwise salvageable 
penumbra into an expanding ischaemic infarct (Heiss, 2012). The 
loss of cellular ATP is thus the primary consequence of cerebral 
ischaemia and the cause of subsequent pathological cascades.
This initial ATP depletion is prolonged by virtue of the 
metabolism of ATP to the purine nucleosides and nucleobases, 
adenosine, inosine and hypoxanthine which leave the brain and 
enter into the general circulation (Kjellmer et al., 1989; Phillis 
et al., 1996a, 1996b; Weigand et al., 1999; Zur Nedden et al., 
2013). This loss from the brain deprives one branch of the purine 
salvage pathway (Figure 1) of the hypoxanthine necessary for the 
formation of the adenine nucleotide backbone of ATP. In addi-
tion, the loss of adenosine from the brain and depletion of the 
primary reservoir of adenosine, ATP, deprives the brain of this 
neuroprotective and anticonvulsant purine nucleoside (Dale and 
Frenguelli, 2009; Pedata et al., 2016; Ribeiro et al., 2016). 
Consequently, for ATP levels to be replenished, resynthesis of the 
adenine nucleotide AMP is a prerequisite.
We have previously shown that a combination of ribose and 
adenine (RibAde) restored ATP levels in the in vitro brain slice to 
levels similar to those observed in vivo, likely by promoting the 
branch of the purine salvage pathway catalysed by adenine phos-
phoribosyltransferase (APRT; Figure 1) (Zur Nedden et al., 2011, 
2014). In addition, we have also demonstrated that this enhanced 
ATP pool translated into greater release of adenosine in response 
to both electrical stimulation of afferent fibres, and oxygen/glu-
cose deprivation (OGD), with increased inhibitory effects on syn-
aptic plasticity and synaptic transmission, respectively. Moreover, 
we observed protective effects of RibAde when given after 6 h of 
OGD in cerebellar granule cells (Zur Nedden et al., 2014).
Given the effects observed in our in vitro experiments, we 
aimed to determine whether RibAde was effective in an in vivo 
model of stroke. From a translational point of view, this is of 
particular interest since both ribose and adenine have previously 
been used in man – ribose as an unregulated nutritional supple-
ment and potential therapy for cardiac disorders (Dhanoa and 
Housner, 2007; Pauly and Pepine, 2000; Pliml et al., 1992; 
Shecterle et al., 2010) and adenine in blood transfusion products 
(Hess and Greenwalt, 2002; Paglia et al., 2016; Peck et al., 1981). 
These compounds thus have strong translational potential in the 
treatment of brain injuries associated with cerebral ischaemia and 
ATP depletion. An additional manipulation of the purine salvage 
pathway was to test the anti-gout medication, allopurinol, to 
establish if, in combination with adenine and ribose, allopurinol 
could further enhance the actions of RibAde, potentially via pre-
venting degradation of salvageable hypoxanthine to the non-sal-
vageable xanthine (Figure 1).
The aim of this study was therefore to assess for the first 
time in vivo the potential of RibAde and RibAde/allopurinol 
(RibAdeAll) in protecting the ischaemic brain in a transient 
middle cerebral artery occlusion (tMCAO) model in rats. Our 
observations reveal that, at appropriate doses, RibAde and 
RibAdeAll are well tolerated and show an encouraging trend 
for reducing cerebral infarction and promoting neurological 
recovery after stroke.
Materials and methods
Animals and study design
All experiments were performed under a licence from the UK 
Home Office and subjected to the Animals (Scientific Procedures) 
Act 1986, incorporating European Directive 2010/63/EU. The 
report was written in accordance with the ARRIVE guidelines 
(http://www.nc3rs.org.uk/arrive). All experiments were per-
formed on male Wistar rats (12–16 weeks, 290–330 g body 
weight) obtained from Harlan, UK. Animals were randomly allo-
cated to the study group using a random list generator (http://
www.random.org). The investigator was blinded to treatment 
until after the analysis was completed.
Preparation of experimental compounds
All reagents were sourced from Sigma–Aldrich. Ribose was 
freely soluble in physiological saline and was delivered intrave-
nously (IV) as an infusion (200 mg/kg/h), which has been used 
previously in studies attempting to restore cardiac adenine nucle-
otides after myocardial ischaemia (Zimmer et al., 1989; Zimmer 
and Ibel, 1984; Zimmer and Schneider, 1991). For adenine, we 
initially aimed for an IV infusion of 50 mg/kg/h based on previ-
ous in vivo studies (Zimmer and Schneider, 1991), but encoun-
tered solubility issues with the free-base of adenine. As the HCl 
salt of adenine could not be used due to the acidity of its solution, 
we initially used the highest soluble dose of the free-base of ade-
nine, which, in our hands, was 36 mg/kg/h. Our initial studies 
were based on this dose, but as toxicity issues were subsequently 
identified, this dose was replaced with an infusion of 10 mg/kg/h. 
The allopurinol solution was given intraperitoneally (IP) as a 
bolus and was prepared at a concentration of 5 mg/mL by dissolu-
tion in 1 mM NaOH, and then brought to a pH of 10 by controlled 
addition of 1 mM HCl and distilled water. Initially, 100 mg/kg 
allopurinol was administered, but this too was reduced to 10 mg/
kg for the main stroke study.
Effects of RibAde on blood pressure
To determine the acute effects of RibAde on cardiovascular 
parameters, we first assessed the effect of RibAde on blood pres-
sure. For that purpose, general anaesthesia was induced with 5% 
isoflurane in nitrous oxide (70%) and oxygen (30%). This was 
followed by oropharyngeal intubation and maintenance of anaes-
thesia through mechanical ventilation with 2% isoflurane at 
3.5 mL stroke volume of nitrous oxide/oxygen mix and 60 
breaths/min. Body temperature was maintained at 37°C ± 0.5°C, 
and the right femoral artery was cannulated with a polythene can-
nula (ID = 0.58 mm and OD = 0.96 mm, Portex Fine Bore poly-
thene tubing; Smiths Medical International Ltd, Kent, England) 
for continuous arterial blood pressure and heart-rate monitoring 
(AcqKnowledge; Biopac Systems, Goleta, CA, USA). Animals 
were randomly assigned to two groups (n = 4 per group) and the 
investigator was blinded to treatment allocation. Group 1: IV 
saline infusion for 3 h at 5 mL/kg/h and group 2: IV RibAde infu-
sion for 3 h (ribose 200 mg/kg/h and adenine 36 mg/kg/h) at 5 mL/
kg/h. One rat assigned to the RibAde group died during the pro-
cedure due to a technical issue. General anaesthesia was main-
tained throughout the whole protocol. At the end of the 3h 
measurement, the rats were killed by cervical dislocation.
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Effects of RibAde and RibAdeAll on stroke 
outcome
The rats were randomly allocated to one of the following groups: 
Control group (6 h IV infusion of saline at 5 mL/kg/h and a single 
IP injection of saline); RibAde group (6 h IV infusion of D-ribose 
(200 mg/kg/h) and adenine (10 or 36 mg/kg/h) in saline delivered 
at 5 mL/kg/h, and single IP injection of saline); and RibAdeAll 
group (as before for the RibAde solution, and a single 10 or 
100 mg/kg IP injection of allopurinol).
The rats were anaesthetised, intubated and ventilated as 
described above. Buprenorphine was injected subcutaneously 
(0.03 mg/kg) at induction and a follow-up dose was administered 
after 8 h for post-stroke analgesia. The right femoral vein was 
cannulated with silicone tubing (ID = 0.51 mm and OD = 0.94 mm, 
Dow Corning Silastic Q7-4750) for the continuous infusion of the 
RibAde solution or saline. tMCAO was induced for 60 min with an 
intraluminal filament (diameter: 0.37–0.39 mm; Doccol, CA, USA) 
as previously described (Longa et al., 1989). The rats were then 
transferred under general anaesthesia for MRI scanning to assess 
the tissue-at-risk of infarction using diffusion-weighted imaging 
(DWI) 50 min after occlusion of the middle cerebral artery.
The animals were then removed from the MRI scanner, and 
60 min after induction of the transient ischaemia, the filament 
was removed to restore blood flow through the MCA. At the time 
of reperfusion, the RibAde or saline infusion was started. A sin-
gle bolus injection of allopurinol (or saline depending on the 
group) was given intraperitoneally at the same time. Infusions 
Figure 1. Degradation and resynthesis of ATP via the purine salvage pathway. ATP is degraded to metabolites such as adenosine, inosine or 
hypoxanthine, which can, via equilibrative transporters, leave cells and enter the blood stream. Purine salvage (blue arrows) restores adenine 
nucleotide levels via hypoxanthine phosphoribosyltransferase (HPRT; hypoxanthine to IMP) and adenine phosphoribosyltransferase (APRT; adenine 
to AMP). This reaction (as does de novo purine synthesis) requires 5-phosphoribosyl-1-pyrophosphate (PRPP), a product of the pentose phosphate 
pathway from which emerges ribose-5-phosphate. An additional source of ribose-5-phosphate is from the isomerisation of inosine-derived ribose-
1-phosphate by phosphopentomutase (black dashed line). Adenine, hypoxanthine and D-ribose are precursors, which enter the salvage pathway. 
Allopurinol inhibits the metabolism of hypoxanthine to xanthine and from xanthine to uric acid. This reduces the production of non-salvageable 
xanthine, makes more hypoxanthine available for salvage and limits the production of hydrogen peroxide (H2O2) and subsequent reactive oxygen 
species. (1) adenylate kinase, (2) ATPases, (3) 5′nucleotidase, (4) adenosine kinase, (5) adenosine deaminase, (6) purine nucleoside phosphorylase, 
(7) xanthine oxidase, (8) ribulose 5-phosphate isomerase, (9) ribokinase, (10) phosphoribosylpyrophosphate synthetase, (11) adenylosuccinate 
synthetase and (12) adenylosuccinate lyase.
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and injections were coded so that the investigator was blind to 
treatment allocation. The rats were allowed to recover, and IV 
infusion was continued for a total period of 6 h while the rats 
were conscious.
After this time, and since the animal was to recover over the 
following week, the intravenous line was tied off and left in place 
under the skin so that the animal was not able to remove it and 
cause a bleed. This is less invasive than surgical removal, did not 
require re-anaesthetising the animal and did not lead to any com-
plications in terms of the use of the limb.
Neurological testing using an 18 point scale (Garcia et al., 
1995) was carried out 24 h, 72 h and 7 days after tMCAO by an 
investigator blind to group identity. At 7 days, the rats were re-
anaesthetised and T2-weighted MRI scanning was performed to 
assess the final infarct size. The rats were then killed by perfu-
sion/fixation and the kidneys collected for histological examina-
tion. The time line of the main stroke study is given in Figure 2.
MRI scanning
MRI was performed on a Bruker Pharmascan 7T/16 cm system 
with a gradient insert (90 mm ID, 300 mT/m) and a 72 mm bird-
cage resonator. A four-channel phased-array rat head surface coil 
was used for brain imaging. DWI was performed at 50 min after 
tMCAO (10 min prior to reperfusion and any treatment) to gener-
ate quantitative apparent diffusion coefficient (ADC) maps and 
to allow assessment of the acute ischaemic injury (i.e. the tissue-
at-risk of infarction). The parameters used were TE 22.8 ms, TR 
4000 ms, 4 shots EPI, 2 averages, 3 directions with b = 0, 1000 s/
mm2, 96 × 96 matrix, 260 µm × 260 µm in-plane resolution, slice 
thickness 1.5 mm, 8 slices. At 7 days post-tMCAO, a RARE 
T2-weighted sequence was used to assess the final infarct size 
(TE 100 ms, TR 5000 ms, Rare factor 8, 2 averages, 256 × 256 
matrix, 98 µm × 98 µm in-plane resolution, slice thickness 
0.75 mm). Quantitative ADC maps were generated from raw 
DWI images, and T2-weighted images were subsequently pro-
cessed using Image J software (http://rsb.info.nih.gov/ij/). The 
tissue-at-risk and final infarct volumes were calculated by man-
ual drawing of the area on each slice. The area generated was 
summed over the number of slices and multiplied by slice thick-
ness for volume calculation as previously described (Baskerville 
et al., 2016), and the lesion size on the T2-weighted images was 
corrected for oedema (Gerriets et al., 2004).
Neurological testing
Animals underwent neurological testing based on an 18 point 
scale (Garcia et al., 1995). Testing was performed prior to 
tMCAO, and on Days 1, 3 and 7 after tMCAO. The scale meas-
ures six parameters assessing motor and sensory functions. The 
scores for each parameter were summed; the minimal score 
achievable (worse neurological status) is 3 and the maximum 
(normal rat) is 18.
Postmortem examinations
Postmortem examinations were conducted by Board-Certified 
veterinary pathologists at various stages of the investigation at 
both the gross and histological level from organs preserved in 
10% formalin. Organ samples were embedded in paraffin wax 
prior to section and staining with haematoxylin and eosin. 
Samples of kidneys, lungs, heart, liver, spleen, pancreas, stom-
ach, small intestine, ceacum, colon, brain and head (multiple sec-
tions including ears, eyes, Hardarian glands, salivary glands, 
nasal cavity and skeletal muscle) were analysed in the rats 
administered the higher doses of compounds (adenine: 36 mg/
kg/h and allopurinol: 100 mg/kg), whereas only the kidneys were 
examined in the rats which had received the lower doses (ade-
nine: 10 mg/kg/h and allopurinol: 10 mg/kg).
Statistical analysis
Data were analysed using SPSS V24 (IBM Corp, Armonk, NY, 
USA). A two-way repeated measures (RM) analysis of variance 
(ANOVA; time and treatment) with Bonferroni post-hoc test to 
correct for multiple comparisons were used to assess the effect of 
treatment on blood pressure, body weight, lesion volume and on 
Figure 2. Time line of the main stroke study.
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neurological status. A one-way ANOVA with Bonferroni post-
hoc tests was used to compare the percentage change in weight 
loss and lesion volume over time. After pooling of the two treat-
ment groups, a Student’s unpaired t-test (two-tailed) was used to 
compare the effect of treatment on the evolution of stroke lesion 
volume (% change over time). A linear regression analysis was 
used to compare acute ischaemic injury (ADC-derived lesion) 
with neurological status at Day 1 post-stroke. ‘n’ refers to the 
number of animals used in the experiment. This study was 
designed as an exploratory investigation aiming to translate, for 
the first time, our previous in vitro results in brain slices to a 
preclinical in vivo model of stroke. As such, sample size calcula-
tions were not performed as there were no comparable previous 
studies from which to obtain estimates of effect size.
Results
Effects of RibAde on blood pressure
An initial pilot series of experiments was carried out in order to 
determine the influence of RibAde on acute changes in blood pres-
sure. For this purpose, we continuously monitored, under general 
anaesthesia, the mean arterial blood pressure (MABP) of two 
groups of rats infused with either a solution of RibAde (ribose 
200 mg/kg/h and adenine 36 mg/kg/h) or with saline for 3 h. 
RibAde administration did not result in a significant difference in 
arterial blood pressure compared to the control group (two-way 
RM ANOVA, treatment effect F(1, 5) = 0.023; p = 0.886; Figure 3).
RibAde and RibAdeAll dose selection
Given the lack of effect of this combination of RibAde on blood 
pressure, we performed an initial series of tMCAO experiments 
using adenine at 36 mg/kg/h IV and allopurinol at 100 mg/kg IP. 
However, we observed an unexpectedly high rate of mortality or a 
need for humane killing after tMCAO in both treated groups. 
Postmortem examination revealed significant renal changes char-
acterised by severe diffuse tubular degeneration, and necrosis 
with hyaline and cellular tubular casts (data not shown). There 
was also evidence of intrapelvic and intratubular calculi, mild 
neutrophilic pyelonephritis and moderate transitional cell hyper-
plasia (data not shown). Both adenine and allopurinol are known 
nephrotoxic agents when administered at high doses (Lindblad 
et al., 1973; Suzuki et al., 1984; Yokozawa et al., 1986) and their 
concurrent administration may have exacerbated their toxic effect.
Following these initial experiments, we then carried out fur-
ther experiments using a lower dose of adenine (10 mg/kg/h IV), 
which maintained the 20:1 ratio of RibAde shown to improve 
tissue ATP levels in brain slices (1 mM ribose and 50 µM ade-
nine) (Zur Nedden et al., 2011). The duration of infusion (6 h) 
was based on previous cardiac studies (Zimmer and Schneider, 
1991) and the dose of allopurinol (10 mg/kg) is one commonly 
used in the rat literature (Suzuki et al., 1984).
We subjected three rats to 200 mg/kg/h IV ribose and 10 mg/
kg/h IV adenine. Two of the rats also received an IP bolus injec-
tion of allopurinol (10 mg/kg) and one received an injection of 
saline. These rats, which were not subjected to transient MCAO, 
were killed 3 days after administration of the compounds, at 
which point there was no discernable effect on the gross condi-
tion of the animals. Postmortem analysis (data not shown) 
indicated that at these doses of adenine and allopurinol, only mild 
renal tubular degenerative changes, with tubular dilation and epi-
thelial atrophy were noted. Consequently, this adenine dose was 
considered safe to assess the effect of RibAde ± allopurinol fol-
lowing tMCAO.
Main study: the effect of RibAde and 
RibAdeAll on stroke outcome
Three groups of animals underwent tMCAO followed by saline 
(IV, n = 6), RibAde (200 mg/kg/hr and 10 mg/kg/hr IV, respec-
tively; n = 8) or RibAdeAll (200 mg/kg/hr and 10 mg/kg/hr IV and 
10 mg/kg IP, respectively; n = 8). As anticipated, the rats in all 
three groups lost weight following surgery due to expected 
decrease in food intake during the recovery period (Figure 4). A 
two-way RM ANOVA (treatment and time) with post-hoc 
Bonferroni correction did not show any interaction between treat-
ment and time in terms of changes in body weight between groups 
(F(2, 19) = 0.776, p = 0.474). A treatment effect was observed (F(2, 
19) = 5.045; p = 0.017) in which a Bonferroni post-hoc test indi-
cated a difference between the RibAde group and the RibAdeAll 
group (p = 0.032), but not in the more relevant comparisons 
between the saline and RibAde groups (p = 1.000) and the saline 
and RibAdeAll groups (p = 0.055). The reason for the difference 
between the RibAde and RibAdeAll groups is unclear. In terms of 
the percentage of body weight lost, a one-way ANOVA and post-
hoc Bonferroni comparison of weight loss between Day 0 (before 
tMCAO) and Day 7 (after tMCAO) did not show any differences 
in percentage weight loss across the three experimental groups 
(F(2, 19) = 0.832, p = 0.450), with the saline-, RibAde- and 
RibAdeAll-treated groups losing (mean ± SD) 9.1% ± 4.4%, 
Figure 3. RibAde had no effect on blood pressure. Mean arterial 
blood pressure prior to and following intravenous infusion of ribose 
and adenine (200 and 36 mg/kg/h IV, respectively; n = 3, blue lines 
and symbols) or saline (n = 4, red lines and symbols) for 3 h, while 
the animals were under general anaesthesia. The graph shows mean 
data ± SD for each group at each time point before (−5 min) and after 
(60, 120 and 180 min) saline or RibAde infusion. Treatment had no 
influence on blood pressure (two-way RM ANOVA, treatment effect F(1, 
5) = 0.023; p = 0.886) over and above the progressive decrease in blood 
pressure seen with time under general anaesthesia. Data points have 
been offset for clarity.
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11.3% ± 6.2% and 8.1% ± 3.8% of body weight, respectively. No 
abnormal clinical signs were noted in the treated rats (with the 
exception of the expected stroke-induced neurological deficits; 
see below). Histopathological analysis of the kidneys (n = 12; four 
randomly selected animals from each group) from these rats at 
Day 7 revealed no abnormality associated with RibAde or 
RibAdeAll treatment compared to animals administered saline 
(Figure 5 for saline and RibAdeAll comparison).
The initial volume of tissue-at-risk of infarction was deter-
mined immediately prior to reperfusion and the onset of treat-
ment (ADC map, Figure 6(a); Day 0). Final infarct volume was 
assessed by T2-weighted imaging at Day 7 (Figure 6(b)). Each 
animal was therefore used as its own control, allowing us to 
assess the effect of reperfusion with or without treatment on the 
extent of tissue salvage over time (Figure 6(c)). A two-way RM 
ANOVA across all animals did not reveal an effect of treatment 
on raw lesion volume (F(2, 19) = 0.206; p = 0.816) or an interac-
tion between treatment and time (F(2, 19) = 2.053; p = 0.156). 
However, an effect may have been obscured by the variability in 
the initial lesion sizes. Accordingly, we compared the change in 
lesion volume over time by expressing the lesion volume at Day 
7 as a percentage of that at Day 0.
Treatment with RibAde or RibAdeAll reduced lesion volume 
by 38% ± 10% (mean ± SEM) and 50% ± 9%, respectively, 
whereas in the saline-treated animals, the reduction in lesion size 
following reperfusion was 18% ± 12% (Figure 6(d)). These val-
ues take into account all animals used in the study, including the 
one animal in the RibAdeAll group that had an unusually large 
lesion at Day 0 and which, in contrast to the other RibAdeAll-, 
and indeed RibAde-treated animals, showed no reduction in 
lesion volume over time (Figure 6(c)). Table 1 provides a statisti-
cal analysis of the percentage change in lesion volume over time 
for all the animals, either comparing all three groups (one-way 
ANOVA), or when the saline group is compared to the combined 
RibAde and RibAdeAll groups (unpaired t-test). These summary 
statistics, together with the individual animal lesion volume tra-
jectories between Day 0 and Day 7 are, on balance, suggestive of 
a positive effect of RibAde-based treatment.
Effect of RibAde and RibAdeAll on 
neurological recovery after stroke
To assess the impact of tMCAO and RibAde-based treatment on 
neurological function, we conducted a neurological assessment 
based on an 18 point scale (Garcia et al., 1995). Plotting of ADC 
lesion volume (prior to both reperfusion and initiation of treat-
ment) against early neurological score (24 h) showed a significant 
inverse relationship between initial lesion volume and neurologi-
cal score measured 24 h after tMCAO (Figure 7(a)). This indicated 
that the 18 point scale reflected stroke-induced brain damage. 
Moreover, segregation by treatment group showed that, by chance, 
animals from the treatment groups displayed larger lesions prior to 
treatment initiation and this was associated with greater neurologi-
cal deficits at 24 h post-stroke; median neurological scores of 9 and 
11 were recorded in the RibAde and RibAdeAll groups, respec-
tively, versus a median score of 13 in the saline group (maximum 
deficit = 3; normal animal = 18; Figure 7(b)). Over the 7-day time 
course, neurological function improved in all groups. However, 
despite being more affected initially, both the RibAde and 
RibAdeAll treatment groups demonstrated an accelerated recovery 
when compared to the saline-treated animals when considering 
daily median neurological scores (Figure 7(b)) or the percentage 
change in mean daily neurological score (Figure 7(c)).
Discussion
In this proof-of-concept study, we provide evidence that 
RibAde ± allopurinol shows promise as a therapy for ischaemic 
brain injury and warrants further investigation in a fully-powered 
pre-clinical study. At the doses and infusion duration used, 
RibAde ± allopurinol showed a strong tendency to increase tissue 
salvage when given in combination with reperfusion and to 
improve functional recovery, while having no major side-effects.
Cerebral ATP during ischaemia: quick to go, 
slow to recover
Depletion of cellular ATP is the initial consequence of an ischae-
mic insult. It is to this that the subsequent pathology that ensues 
can be attributed. While attempts have been made to improve 
brain energy metabolism and cerebral bioenergetics after brain 
injury, these have revolved around targeting mitochondria and 
oxidative phosphorylation via the provision of substrates that feed 
into the tricarboxylic acid cycle such as glucose, lactate and pyru-
vate (Dienel, 2014), as well as ketones such as β-hydroxybutyrate 
(Prins and Matsumoto, 2014). These studies, albeit with occa-
sional successes, have not led to treatments for the injured brain. 
Figure 4. RibAde or RibAdeAll had no effect on stroke-induced weight 
loss. Body weight immediately before (Day 0) and 7 days after tMCAO 
(final time point) with mean value for each group and time point 
shown as a horizontal black bar. All animals show a decrease in body 
weight secondary to general anaesthesia and stroke surgery. While 
a two-way RM ANOVA identified a significant effect of treatment 
(F(2, 19) = 5.04; p = 0.017), post-hoc Bonferroni comparison showed 
no difference between the saline and RibAde (p = 1.000) groups, 
nor between the saline and RibAdeAll groups at Day 0 and Day 7 
(p = 0.055). There were no differences in the percentage weight 
loss across the three experimental groups (mean ± SD; n): saline 
(9.1% ± 4.4% of initial body weight; 6), RibAde (11.3% ± 6.2%; 8), 
RibAdeAll (8.1 ± 3.8%; 8); one-way ANOVA (F(2, 19) = 0.832, p = 0.450).
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This is likely due to the fact that mitochondria are damaged after 
trauma/ischaemia, and the activity of the electron transport chain, 
upon which the synthesis of ATP depends, will be severely 
impaired, if not harmful in the production of reactive oxygen spe-
cies (Bakthavachalam and Shanmugam, 2017). In addition, since 
the mitochondrial ATP synthase converts ADP to ATP, it thus 
absolutely relies upon the cytosolic purine salvage pathway to 
provide it with the necessary adenine nucleotide backbone upon 
which to affix additional phosphate groups. Unfortunately, the 
substrates for the purine salvage pathway are lost to the general 
circulation after cerebral ischaemia, which likely explains the 
slow recovery of cerebral ATP after injury.
Therapies to restore ischaemia-depleted ATP: 
lessons from the heart
This fundamental issue has been appreciated in the cardiac litera-
ture and there have been, and indeed continue to be, attempts to 
redress the basis of ATP depletion (loss of nucleosides and nucle-
obases) seen in myocardial ischaemia, which similarly arises 
through the loss to the general circulation of substrates for the 
purine salvage pathway. Initially, these studies in the 1980s 
revolved around the use of pentose sugars such as ribose, which, 
via the action of ribokinase is converted to ribose-5-phosphate 
(Figure 1). Ribose-5-phosphate is then incorporated into the 
phosphoribosyl pyrophosphate pool, from which a phospho-
ribose group is used by cytosolic APRT and HPRT to generate 
purine mononucleotides, including AMP (Figure 1). Through the 
actions of adenylate kinase, several isoforms of which are cyto-
solic and found in brain, AMP can be converted to ATP 
(Panayiotou et al., 2014). Importantly, adenylate kinases are pro-
miscuous in that they can utilise nucleotide triphosphate donors 
other than ATP, such as GTP, which are largely preserved during 
cerebral ischaemia (Hagberg et al., 1987); this avoids the futile 
cycle of robbing ATP to pay ADP. Such a cytosolic ATP-
generating system is necessary in highly polarised cells such as 
neurons where mitochondria may be some distance away, and 
indeed essentially absent from most excitatory synapses on den-
dritic spines (Kasthuri et al., 2015).
In the perfused heart, administration of ribose increased the 
rate of recovery of adenine nucleotides in acute models of high 
energy demand such as isoproterenol challenge (Zimmer, 1983; 
Zimmer et al., 1980, 1984; Zimmer and Gerlach, 1978) or 
ischaemia-reperfusion insult (Zimmer and Ibel, 1984) while 
studies in chronic models show more conflicting results (Faller 
et al., 2013; Lamberts et al., 2007; Zimmer et al., 1989). 
Additional benefits for ATP production were observed via the 
inclusion of adenine (Zimmer, 1998). However, the nephrotoxic 
actions of adenine following its xanthine oxidase-mediated con-
version to the insoluble 2,8 dihydroxyadenine, together with the 
high doses administered in early studies (Zimmer and Schneider, 
1991) and the prolonged (24–48 h) intracardiac perfusion of 
ribose/adenine solution (St Cyr et al., 1986; Ward et al., 1983, 
1984) has not led to a continuation of this approach.
Figure 5. Histological examination of the kidney of one representative saline control animal (a1 and a2) and one RibAdeAll-treated animal 
(200 mg/kg/hr, 10 mg/kg/hr IV and 10 mg/kg IP, respectively; b1 and b2) at low (a1 and b1) and high magnification (a2 and b2). No structural 
abnormalities were detected in RibAde- or RibAdeAll-treated animals 7 days after infusion. Light microscopy images of H&E staining.
8 Brain and Neuroscience Advances 
Cardiac ATP repletion strategies in ATP-
depleted brain tissue
Given that no work on cerebral bioenergetics had been done in 
brain tissue with RibAde, we initially examined the influence of 
RibAde in acutely-prepared rat brain slices; tissue that is known 
to have lower levels of ATP than the intact brain, likely due to the 
ischaemia and trauma associated with their preparation. Indeed, 
this has led some to describe the brain slice as a model for the 
post-traumatic, post-ischaemic brain (Hossmann, 2008).
Incubation of neocortical/hippocampal slices in modest con-
centrations of ribose (1 mM) and adenine (50 µM) for 2–3 h 
resulted in stable elevations in cellular ATP, which, when the 
dead edges of brain slices were taken into account, reached val-
ues of ATP comparable to those reported in the literature for the 
in vivo rat brain (Zur Nedden et al., 2011). The elevation in tissue 
Figure 6. RibAde and RibAdeAll show a tendency to reduce stroke lesion volume. (a) Representative coronal MRI scans of the same animal 
(RibAdeAll group) at the level of the caudate nuclei during ischaemia (a) and 7 days after reperfusion (b). The manually determined lesion 
boundaries are highlighted in yellow. (a) The ADC (apparent diffusion coefficient) map derived from the DWI scan acquired 50 min after tMCAO, 
just prior to reperfusion, shows the tissue-at-risk of infarction as a hypo-intense signal. (b) A T2-weighted MRI scan shows the final infarct area 
(hyper-intense) assessed 7 days later. In this RibAdeAll-treated animal, there was a 50% reduction in lesion volume between the two time points. 
(c) Individual paired measurements of lesion volume at Day 0 (DWI) and Day 7 (T2-weighted imaging) in the three experimental groups of animals 
showing a consistent trend for substantial lesion shrinkage in the RibAde (blue; n = 8) and RibAdeAll (green; n = 8) groups compared to saline 
controls (red; n = 6). Black bars show mean lesion volume by day. (d) Change in lesion volume between Days 0 and 7 normalised to lesion size on 
Day 0. Mean lesion size (open circles) decreased by 38% in the RibAde group, 50% in the RibAdeAll group and 18% in the saline group. p = 0.065 
between untreated and treated groups (t-test). Horizontal line, median; box 25%–75% range; whiskers, ±1 SD; X, min and max values.
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ATP translated into greater release of adenosine into the extracel-
lular space during electrical stimulation of afferent fibres (Zur 
Nedden et al., 2011) and in response to OGD (Zur Nedden et al., 
2014). This increased adenosine release exerted an enhanced 
inhibitory action on excitatory synaptic transmission. Considering 
these two actions in the context of the energetically compromised 
intact brain, the enhancement of tissue ATP would allow better 
restoration and maintenance of cellular ionic homeostasis and 
reduce the prevalence and severity of anoxic depolarisation inva-
sion of the adjacent penumbra. This would be complemented by 
the enhanced inhibitory action of greater adenosine release on 
neuronal function in terms of both reducing glutamate release 
and neuronal excitability. To test the potential benefits of RibAde 
in vivo, we thus adopted a model of cerebral ischaemia in which 
ATP depletion is known to occur (Hata et al., 1998).
In vivo treatment with RibAde ± allopurinol 
produced no major side effects
We initially strove to assess the safety of the treatment. First, 
we evaluated the effect of RibAde on blood pressure. Prior 
studies suggested that infusion of adenine (at 50 mg/kg/h IV) 
could decrease MABP (Zimmer and Schneider, 1991). A sig-
nificant decrease in MABP would compromise cerebral blood 
flow, increasing the severity of the ischaemic insult and the 
amount of permanent brain damage. At a higher dose of ade-
nine (36 mg/kg/h IV) than the one used in the main stroke 
study (10 mg/kg/h IV), we detected no significant effect of 
RibAde on blood pressure. Second, having encountered mor-
tality and kidney damage associated with the 36 mg/kg/h infu-
sion, it was necessary to confirm that the lower infusion dose 
chosen for the main study (10 mg/kg/h IV) had no major con-
sequences on general health.
Using adenine at 10 mg/kg/h, not only did the treated animals 
recover and survive for 7 days following tMCAO, the treatment 
also had no effect per se on body weight or the general condition 
of the animals compared to saline-treated controls. Although we 
did not measure blood markers of renal function, the former sug-
gests that the rats did not suffer from clinical renal failure, which 
results in decreased food intake (Lindblad et al., 1973). Minor 
transient histopathological kidney changes attributed to adenine, 
which were noted 3 days after infusion in the preliminary study, 
had resolved by Day 7 in kidney histology data from the main 
study.
Similar doses of adenine (10 mg/kg IV) have been adminis-
tered to humans, albeit over shorter durations (up to an hour), 
with no effect on renal function (Bartlett, 1977; Roth et al., 1975) 
and a higher acute dose (25 mg/kg in 1 h) was administered to 
non-human primates with no apparent consequences (Siegel 
et al., 1971). This highlights the significant potential for rapid 
translation to human studies as all compounds used in this study 
have already been used in man for various purposes. Adenine has 
been used for decades for the preservation of blood products 
(Hess and Greenwalt, 2002; Paglia et al., 2016; Peck et al., 1981), 
most likely for the maintenance of erythrocyte ATP, while allopu-
rinol, a xanthine oxidase inhibitor, is a common treatment for 
gout and has been since the 1960s. Finally, D-ribose has been 
used as an ergogenic aid (Dhanoa and Housner, 2007) or a sup-
plement for cardiac disease (Bayram et al., 2015; Pauly and 
Pepine, 2000; Pliml et al., 1992; Shecterle et al., 2010) and can be 
tolerated in man for prolonged periods at intravenous doses 
higher than those used in this study (Gross and Zollner, 1991).
RibAde ± allopurinol: trend towards decreased 
infarct size and improved functional outcome 
in a pre-clinical stroke model
Our results constitute the first in vivo proof of concept of the 
potential of RibAde to protect penumbral tissue. Following a 1h 
ischaemia period, reperfusion reduced lesion size by 18% in the 
control group, by 38% in the RibAde group and by 50% in the 
RibAdeAll group. In addition, this appears to be linked to a faster 
neurological recovery. The rank order of these benefits is consist-
ent with our hypothesis concerning the targeting of the purine 
salvage pathway in the direct (RibAde) and indirect (allopurinol 
leads to greater availability of endogenous hypoxanthine) provi-
sion of substrates with which the brain can make ATP in a manner 
that is independent of mitochondria.
These findings thus vindicate our extensive in vitro evidence 
of the beneficial effects of RibAde enhancing cellular ATP levels, 
promoting increased adenosine release and reducing cell death 
after OGD (Zur Nedden et al., 2011, 2014). Beneficial effect of 
allopurinol have been described in various animal models of 
brain injury including cerebral ischaemia (Akdemir et al., 2001; 
Ansari et al., 2013; Dong et al., 2015; Isik et al., 2005; Martz 
et al., 1989), but have been mostly described in terms of its anti-
oxidant properties, although maintenance of the cerebral adenine 
nucleotide pool during ischaemia has been reported (Phillis et al., 
Table 1. Statistical comparison of the percentage change in lesion volume between Day 0 and Day 7 across the groups of animals used in the study. 
Test Group N Mean lesion 
volume at Day 7 
(% Day 0)
SD Statistics 
(F or t)
DF p-value Sig.
One-way ANOVA Saline 6 82.4 30.4 2.247 2, 19 0.133 NS
 RibAde 8 62.5 27.7  
 RibAdeAll 8 50.5 26.3  
Unpaired t-test Saline 6 82.4 30.4 1.951 20 0.065 NS
 RibAde/All 16 56.5 26.8  
A one-way ANOVA was conducted across the three groups (Saline, RibAde and RibAdeAll). An unpaired t-test was conducted between saline and the combined treatment 
groups (RibAde and RibAdeAll).
Number of animals (N); standard deviation (± 1 SD); degrees of freedom (DF); not significant (NS).
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1995). A further advantage of the inclusion of allopurinol is that 
it would reduce the xanthine oxidase-mediated conversion of 
adenine to the insoluble and nephrotoxic 2,8-dihydroxyadenine.
The reduction of the injury in the treated groups likely reflects 
sparing of penumbral tissue. This would be consistent with assess-
ment of neurological deficit over the first week following stroke, 
which demonstrated a trend to faster recovery in the treatment 
groups despite having larger lesions prior to the start of treatment. 
We hypothesise that RibAde in conjunction with allopurinol 
improves cellular metabolism of the ischaemic brain by allowing 
quicker replenishment of ATP levels by its purine saving effect as 
suggested by our in vitro experiments (Zur Nedden et al., 2011). 
Maintenance of ATP levels would be beneficial for multiple rea-
sons. First, a large amount of energy is required by the neuronal 
Figure 7. Trend towards an improvement in neurological outcome after stroke in RibAde and RibAdeAll groups. All animals scored the maximum 
value of 18 prior to tMCAO (dashed line on panels (a) and (b)). (a) Correlation between neurological score at 24 h after tMCAO (out of 18; 
18 = normal animal, dashed line; 3 is the lowest possible score) and volume of tissue-at-risk of infarction assessed on ADC maps at the end of tMCAO 
and prior to reperfusion and the start of saline (red circles), RibAde (blue circles) or RibAdeAll (green circles) treatment. Considering all animals, 
there was a significant inverse correlation between neurological score and lesion volume prior to treatment (linear regression, p = 0.0015, R2 = 0.40). 
Note the coincidental clustering of RibAde/RibAdeAll-treated animals with larger pre-treatment lesion volumes. (b) Median neurological scores (out 
of 18; dashed line) per group on Days 1, 3 and 7 after induction of stroke (n = 8 in RibAde and RibAdeAll groups and n = 6 in saline group). Vertical 
lines indicate the first and third quartiles for each data point. Median and quartile values are rounded to nearest whole number. Data points for 
each group have been offset for clarity. (c) Mean neurological scores (± SEM) for each day normalised to Day 1 revealed a trend to faster recovery, 
despite larger initial lesions in the treatment groups, consistent with the greater reduction in lesion size (Figure 6). However, statistical analysis of 
the effect of treatment on the evolution of the neurological score did not reach significance (two-way repeated-measures ANOVA with treatment and 
time effect; treatment effect F(2, 19) = 0.678; p = 0.519). Data points for each group have been offset for clarity.
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Na+/K+ ATPase in order to maintain cellular homeostasis and 
viability (Harris et al., 2012). Following ischaemia, failure of 
energy-dependent membrane ion pumps leads to cytotoxic 
oedema, depolarisation and excitotoxicity, which ultimately leads 
to cell death (Doyle et al., 2008). Second, adenine nucleotides are 
a source of adenosine, a known neuroprotective, anticonvulsant 
and vasodilator metabolite of ATP (Pedata et al., 2016; Ribeiro 
et al., 2016). Adenosine would thus be expected to protect neural 
tissue from excitotoxic damage, prevent peri-infarct depolarisa-
tions from the ischaemic core, suppress seizures and further brain 
damage. Finally, by its vasodilatatory properties, adenosine 
release could also improve blood supply to the penumbral area 
allowing further protection (Dale and Frenguelli, 2009; Williams-
Karnesky and Stenzel-Poore, 2009).
Study limitations
The main limitation of this study resides in the low number of 
animals in each group. This is compensated for to a certain extent 
by serial MRI scanning and sequential neurological testing, 
which allowed each animal to be used as its own control, and 
thereby decreasing markedly the number of animal required in 
such a variable model to draw valid conclusions. However, 
despite this and the trend towards a reduction in lesion volume in 
a manner consistent with our hypothesis, the results did not reach 
statistical significance. Similarly, the trend towards enhanced 
neurological recovery in RibAde- or RibAdeAll-treated animals 
was compelling, but lacked clear statistical support. Although the 
18 point neurological testing used here assessed both sensory and 
motor function, it remains a crude way to assess function. More 
refined tests, including of balance, such as the staircase or cylin-
der tests (Schaar et al., 2010), or the modified Neurological 
Severity Score (mNSS) (Chen et al., 2001)) could potentially 
have detected more subtle improvements in the RibAde/All-
treated groups.
Future work will assess whether RibAde ± allopurinol prove 
to be beneficial in various models of focal cerebral ischaemia 
including permanent middle cerebral artery occlusion models, 
and in aged animals with or without co-morbidities such as 
hypertension and diabetes. Based on data from this study, 13 ani-
mals per group would be required to show a significant differ-
ence (p < 0.05; power of 0.8) in lesion volume between saline- and 
RibAdeAll-treated animals of the magnitude reported in this 
study (~32% difference) and an SD of 28%. Confirmation of the 
mode of action of RibAde will be sought by studying cerebral 
metabolism with 31P-MRS, allowing quantification of ATP over 
time in vivo, or to use NMR to follow the metabolic fate of 
labelled RibAde in microdialysate samples. The duration of treat-
ment, dose of allopurinol and the potential inclusion of other neu-
roprotective compounds, such as uric acid (Llull et al., 2016), are 
additional variables that could be explored.
Conclusion
In this study, we have obtained encouraging preliminary evi-
dence, based upon extensive in vitro studies, that ribose, adenine 
and allopurinol have the potential to protect the ischaemic brain 
in a rat model of tMCAO. Following further validation, we 
believe that it would be a readily translatable treatment for acute 
injuries of the human brain such as traumatic brain injury and 
stroke. The tolerability of the compounds at the doses used, plus 
their prior use in various indications, together with a defined sci-
entific rationale and identified mechanism of action should facili-
tate translational studies, not just in the clinic, but at the point of 
injury by attending paramedics.
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